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http://dx.doi.org/10.1016/j.pedneo.2Background: Nitric oxide (NO) deficiency occurs in humans and animals with hypertension and
chronic kidney disease (CKD). An inhibitor of NO synthase, NG-nitro-L-arginine methyl ester (L-
NAME) exacerbates kidney damage in the adult spontaneously hypertensive rat (SHR). We
examined whether L-NAME exacerbated hypertensive nephrosclerosis in young SHRs and
whether melatonin protects SHRs against kidney damage by restoration of the asymmetric di-
methylarginine (ADMA)eNO pathway.
Methods: Rats aged 4 weeks were randomly assigned into three groups (n Z 10 for each
group): Group 1 (control), SHRs without treatment; Group 2 (L-NAME), SHRs received L-NAME
(80 mg/L) in drinking water; and Group 3 (L-NAME þmelatonin), SHRs received L-NAME (80 mg/
L) and 0.01% melatonin in drinking water. All rats were sacrificed at 10 weeks of age.
Results: L-NAME exacerbates the elevation of blood pressure, renal dysfunction, and glomer-
ular sclerosis in young SHRs. L-NAME induced an increase of ADMA and a decrease of arginine-
to-ADMA ratio in the SHR kidney. Melatonin therapy prevented L-NAME-exacerbated hyperten-
sion and nephrosclerosis in young SHRs. In addition, melatonin restored L-NAME-induced reduc-
tion of dimethylarginine dimethylaminohydrolase (DDAH; ADMA-metabolizing enzymes)
activity in the SHR kidney. Next, melatonin decreased renal ADMA concentrations, increased
renal arginine-to-ADMA ratio, and restored NO production in L-NAME-treated young SHRs.
Moreover, melatonin reduced the degree of oxidative damaged DNA product, 8-t of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of
m (Y.-L. Tain).
are co-first authors.
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190 M.-C. Cheng et alhydroxydeoxyguanosine immunostaining in L-NAME-treated SHR kidney.
Conclusion: Our results indicated that L-NAME/SHR is a useful model for hypertensive nephro-
sclerosis in young rats. The blood pressure-lowering and renoprotective effects of melatonin is
due to increases of DDAH activity, decreases of ADMA, and reduction of oxidative stress in L-
NAME-treated SHR kidney. Specific therapy targeting the DDAHeADMA pathway may be a prom-
ising approach to slowing chronic kidney disease progression in children.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Nitric oxide (NO) deficiency occurs in humans and animals
with hypertension and chronic kidney disease (CKD).1,2
Asymmetric dimethylarginine (ADMA), an endogenous in-
hibitor of NO synthase (NOS), can reduce the synthesis of
NO. Elevated ADMA levels are observed in patients with
hypertension, CKD, and many other clinical disorders.3
Several experimental models for producing renal failure
from hypertension have been developed. Among them,
aging spontaneously hypertensive rats (SHRs) naturally
develop CKD, which mimics patients with essential hyper-
tension.4 When the NOS inhibitor NG-nitro-L-arginine methyl
ester (L-NAME) was administered to adult SHRs, rats
exhibited glomerulosclerosis and renal failure, which are
similar to those observed in aging SHRs.5
We recently observed that melatonin, an indoleamine
produced by the pineal gland, concurrently prevents the
increases in ADMA and hypertension in young SHRs.6 We also
noted that the blood pressure-lowering effect of melatonin
is, at least in part, due to the increases of renal dimethy-
larginine dimethylaminohydrolase (DDAH; ADMA-
metabolizing enzymes) activity to decrease ADMA in
young SHRs.6 Our other report indicated that the SHR kid-
ney might be protected against injury via a reduction in the
renal ADMA concentration.7
Although L-NAME/SHR is a useful model for hyperten-
sive nephrosclerosis in adult rats,5 whether L-NAME
induced renal dysfunction and glomerular injury in young
SHRs to represent childhood CKD remains unknown. We
therefore designed this study to examine whether L-
NAME-treated young SHRs develop accelerated kidney
damage and increased ADMA. We also examined whether
melatonin not only prevented ADMA increases but also
reversed L-NAME-exacerbated hypertensive nephro-
sclerosis in young SHRs.
2. Methods
This experiment was approved and performed under the
Guidelines for Animal Experiments of Chang Gung Memorial
Hospital and Chang Gung University. Male SHRs at 3 weeks of
age were obtained (BioLASCO Taiwan Co., Ltd., Taipei,
Taiwan). Rats were housed and maintained in an Association
for Assessment and Accreditation of Laboratory Animal Care
International-accredited facility with free access to tap
water and standard rat chow. Rats aged 4 weeks were
randomly assigned into three groups (nZ 10 for each group):
Group 1 (control), SHRs without treatment; Group 2(L-NAME), SHRs received L-NAME (80mg/L) in drinkingwater;
and Group 3 (L-NAME þ melatonin), SHRs received L-NAME
(80 mg/L) and 0.01% melatonin in drinking water.6 We
treated young SHRs with L-NAME at the dosage of 80 mg/L,
which has been used in adult SHRs to induce kidney damage.5
Blood pressure was measured in conscious rats by an indirect
tail-cuff method (BP-2000; Visitech Systems, Inc., Apex, NC,
USA) after systematic training at 4 weeks and 10 weeks of
age. Three stable consecutive measures were taken and
averaged. All rats were sacrificed at 10 weeks old. Twenty-
four-hour urine collections were performed prior to sacri-
fice for the determination of clearance of creatinine. Urinary
protein excretion was determined by the Bradford method,
as published previously.6 Heparinized blood samples were
collected, and the kidneys and heart were harvested. One
kidney was removed and snapped frozen; the other kidney
was perfusion fixed and removed for immunohistochemistry.
8-Hydroxydeoxyguanosine (8-OHdG) is a damaged DNA
product. Plasma 8-OHdG levels were measured using a
commercial kit (Enzo Life Sciences, Inc., Farmingdale, NY,
USA). Western blot analysis was conducted on kidney cortex
(100e200 mg total protein) using a mouse monoclonal anti-
body (SantaCruz Biotechnology Inc., SantaCruz, CA,USA) for
neuronal NOS (nNOS) detection. Membranes were stripped
and reprobed for endothelial NOS (eNOS) using a mouse
monoclonal antibody (Transduction Laboratories, Lexington,
KY, USA). For DDAH, we used a goat anti-rat DDAH1 antibody
(Santa Cruz Biotechnology Inc.; 1:500 dilution, overnight
incubation) and a goat anti-rat DDAH2 antibody (Santa Cruz
Biotechnology Inc.; 1:100 dilution, overnight incubation),
followed by a secondary donkey anti-goat antibody (Santa
Cruz Biotechnology Inc.; 1:2000 dilution, 1 hour incubation).
Bands of interest were visualized using SuperSignalWest Pico
reagent (Pierce, Rockford, IL, USA) and quantified by densi-
tometry as integrated optical density (IOD) factored for
Ponceau red staining (PonS) to correct for any variations in
total protein loading and for an internal standard. The pro-
tein abundance was represented as IOD/PonS. All details of
these measurements were reported in our previous study.6
Kidney L-arginine and ADMA levels were measured using
high performance liquid chromatography (HPLC; HP series
1100; Agilent Technologies, Inc., Santa Clara, CA, USA) with
the OPAe3MPA derivatization reagent, as described previ-
ously.6 Standards contained concentrations of L-arginine
and ADMA in the range of 1e100 and 0.5e5 mm, respec-
tively. The recovery rate was approximately 90%. The tissue
concentration was factored for protein concentration,
which was represented as mM/g protein.
Pathology was performed on 5-mm sections of formalin-
fixed kidney, blocked in paraffin wax, and stained with
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on a blinded basis by determining the sclerotic damage to
glomeruli using the 0e4þ scale, and it was graded as fol-
lows: 0, no changes; 1þ injury involved <25% damage to
the glomerulus; 2þ injury, 25e50%; 3þ injury, 50e75%; and
4þ injury, 75e100% damage. Data were represented as
percentage of damaged glomeruli (n Z 100) showing any
level of injury (scale from 1þ to 4þ), as published previ-
ously.8 Immunohistochemical staining was performed using
anti-8-OHdG antibody (1:2500; Santa Cruz Biotechnology
Inc.) with a supersensitive polymer-horseradish peroxidase
(HRP) IHC detection kit (BioGenex, San Ramon, CA, USA), as
described previously.6 Identical staining omitting incuba-
tion with primary antibody was used as a negative control.
DDAH activity was measured by a colorimetric assay
measuring the rate of citrulline production, which we
recently optimized.9 The DDAH activity was represented as
mM citrulline formation/g protein/minute at 37 C.
NO production was measured by electron paramagnetic
resonance (EPR) spectroscopy with spin probe N-methyl-D-
glucamine dithiocarbamate (MGD) and FeSO4, as described
previously.10 Samples were placed in a 50-mL glass capillary
(Wilmad Glass, Buena, NJ, USA). The EPR spectra were
recorded using an EMX Plus EPR spectrometer (Bruker Bio-
spin, Rheinstetten, Germany) equipped with an EMXem40X
microwave bridge operating at 3.16 G.
Results were expressed as mean  standard error of
mean (SEM). Biochemical parameters were analyzed by
one-way analysis of variance (ANOVA) with the post hoc
least significant difference (LSD) test. All analyses were
performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). A
p-value < 0.05 was considered statistically significant.3. Results
The mortality rate for the control group, L-NAME group, and
L-NAME þ melatonin group were 10% (1/10), 20% (2/10),
and 10% (1/10), respectively. As shown in Table 1, bothTable 1 Weights and functional parameters.
Control (n Z
Mortality (%) 10
Body weight (g) 271.5  3.5
Heart weight (g) 1.16  0.03
Heart weight per 100 g body weight 0.44  0.01
Left kidney weight (g) 1.39  0.04
Left kidney weight per 100 g body weight 0.5  0.02
Systolic blood pressure (mmHg) 165  3
Diastolic blood pressure (mmHg) 118  5
Mean arterial pressure (mmHg) 134  3
CCr, mL/min/kg body weight 0.69  0.05
Glomerular injury index score 4.6  0.7
Urinary protein excretion (mg/24 h/100 g
body weight)
6.54  0.44
NO production (arbitrary units) 2146  240
*p < 0.05 vs. control.
yp < 0.05 vs. L-NAME.
CCr Z clearance of creatinine; L-NAME Z NG-nitro-L-arginine methylL-NAME-treated groups had lower body weight than con-
trols. The heart weight-to-body weight ratio was greater in
the L-NAME group than controls, which was prevented by
melatonin therapy. Systolic and diastolic blood pressures,
and mean arterial pressure were markedly increased in the
L-NAME group, which melatonin prevented.
There was a significant decrease in the clearance of
creatinine (CCr) level in the L-NAME group versus the con-
trols. Renal pathology revealed that glomerular injury
index scores were higher in the L-NAME group than in the
controls. As shown in Figure 1, glomerulosclerosis was
present in L-NAME-treated SHRs. Tubulointerstitial fibrosis
developed in parallel with glomerulosclerosis. These
changes contrasted to the milder injury observed in the L-
NAME þ melatonin group. Next, urinary protein excretion
was greater in the L-NAME group than that in the control
group, which was prevented by melatonin therapy (Table
1). CCr level, proteinuria, and glomerular injury index
scores demonstrated that the L-NAME group had the worst
renal outcome among the three groups. However, mela-
tonin therapy significantly improved the renal outcome in
the L-NAME þ melatonin group.
In the kidney, L-arginine level was not different among
the three groups (Figure 2A). Renal ADMA level was higher
in the L-NAME group than in the control group (Figure 2B).
However, melatonin significantly reduced renal ADMA con-
centration in L-NAME-treated SHRs. By contrast, the renal
arginine-to-ADMA ratio was significantly decreased in the L-
NAME group, which was prevented by melatonin therapy
(Figure 2C). Next, we determined NO levels in the SHR
kidneys using EPR with spinning trap. Renal NO production
was lower in the L-NAME group than that in the control
group, which melatonin prevented (Table 1).
Next, we found no difference in renal protein levels of
eNOS, nNOS, DDAH-1, and DDAH-2 among the three groups
(Figure 3AeE). Renal DDAH activity was significantly
decreased in the L-NAME group versus the control group.
Melatonin therapy prevented the reduction of renal DDAH
activity in L-NAME-treated SHRs (Figure 3F).9) L-NAME (n Z 8) L-NAME þ melatonin
(n Z 9)
20 10
186.5  12.9* 197.2  16.5*
1.18  0.03 1.20  0.06
0.74  0.04* 0.59  0.03y
1.04  0.04 1.0  0.06
0.54  0.01 0.49  0.03
176  2* 167  2y
129  5* 111  6y
145  4* 130  4y
0.37  0.03* 0.75  0.18y
9.9  1.5* 4.9  0.9y
29.54  1.94* 5.94  1.44y
1095  71* 1748  240y
ester; NO Z nitric oxide.
Figure 1 Histological changes in SHR kidneys by periodic acideSchiff stain. Representative photographs from the controls showed
that the glomeruli are normocellular, the tubules are closely spaced, and the interstitium and blood vessels are not prominent
(upper left panel). Histological changes in SHRs treated with L-NAME revealed that the glomeruli are mildly affected with focal
glomerular sclerosis (arrowhead). The tubules show atrophy and focal drop-out (arrow). The subcapsular interstitial spaces are
infiltrated with chronic inflammatory cells (asterisk), mainly mononuclears and lymphocytes (upper right panel). By contrast,
representative photographs from SHRs treated with L-NAME þ melatonin showed that the glomeruli are normocellular, the tubules
are closely spaced, and the interstitium is not prominent (lower left panel). Scale bar Z 100 mm. L-NAME Z NG-nitro-L-arginine
methyl ester; SHR Z spontaneously hypertensive rat.
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both cytoplasmic and nuclear 8-OHdG in the glomeruli and
renal tubules indicated little staining in the control group,
an intermediate level of staining in the L-NAME þmelatonin
group, and intense staining in the L-NAME group. With re-
gard to increased 8-OHdG staining in the L-NAME-treated
SHR kidney, we found that plasma 8-OHdG level was
significantly increased in the L-NAME group versus the
control group (Figure 4B). Melatonin therapy prevented the
increases of plasma 8-OHdG levels in L-NAME-treated SHRs.4. Discussion
This study provides insight into a novel mechanism by which
L-NAME impairs the DDAHeADMA pathway and exacerbates
kidney injury in young SHRs. Taken together, our results can
be summarized as follows: (1) L-NAME exacerbates renal
dysfunction and glomerular sclerosis in young SHRs, which
are correlated with increased ADMA and decreased arginine-
to-ADMA ratio in the kidneys; (2)melatonin reverses L-NAME-
exacerbated hypertension and nephrosclerosis in young
SHRs; (3) melatonin increases renal arginine-to-ADMA ratio
but decreases renal ADMA concentration in L-NAME-treated
young SHRs; and (4) melatonin restores L-NAME-induced
reduction of DDAH activity in the SHR kidney.SHRs exhibited an increase in blood pressure starting
from 5e6 weeks of age, a steep increase between 6 weeks
and 20 weeks of age, and progressive development of many
features of hypertensive end-organ damage. Unlike salt-
sensitive hypertensive models, SHR is resistant to kidney
damage.11 In accordance with previous findings in adult
rats,5 our present study demonstrates for the first time that
L-NAME/SHR is a useful model for hypertensive nephro-
sclerosis in young rats. This model may provide insights into
studying hypertension-induced kidney damage in childhood
CKD in the future.
Our previous study showed that the restoration of
increased ADMA and reduced arginine-to-ADMA ratio by
melatonin was associated with a decrease in blood pressure
in young SHRs.6 In this study, we further demonstrated that
melatonin prevented L-NAME-exacerbated hypertensive
nephrosclerosis in young SHRs. L-NAME is a non-selective
NOS inhibitor. Therefore, L-NAME aggravated glomerular
sclerosis and renal function impairment indicating that NO
plays a protective role against kidney damage in SHRs.
Recently, we observed that the accumulation of ADMA in
the kidneys is primarily due to impaired ADMA catabolism,
secondary to decreased DDAH activity.6 In this study, we
found that melatonin increased DDAH activity, slowing the
accumulation of ADMA in L-NAME-treated SHR kidneys. In
addition, melatonin prevented decreases in the arginine-
Figure 2 (A) L-Arginine, (B) ADMA, and (C) arginine-to-ADMA ratio in the kidney in controls, SHRs treated with L-NAME, and SHRs
treated with L-NAME þ melatonin. *p < 0.05 vs. control. yp < 0.05 vs. L-NAME group. ADMA Z asymmetric dimethylarginine; L-
NAME Z NG-nitro-L-arginine methyl ester; SHR Z spontaneously hypertensive rat.
Figure 3 Representative Western blots (A) show renal (B) eNOS (150 kDa), (C) nNOS (160 kDa), (D) DDAH-1 (34 kDa), and (E) DDAH-2
(30 kDa) bands; (F) renal DDAH activity detected by a colorimetric assay. *p < 0.05 vs. control. yp < 0.05 vs. L-NAME group.
DDAHZ dimethylarginine dimethylaminohydrolase; eNOS Z endothelial nitric oxide synthase; L-NAMEZ NG-nitro-L-arginine methyl
ester; nNOSZ neuronal nitric oxide synthase.
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Figure 4 (A) Light micrographs illustrating immunostaining for 8-OHdG in the kidney in controls, SHRs treated with L-NAME, and
SHRs treated with L-NAME þ melatonin. NZ 3/group. Scale barZ 50 mm. (B) Effect of melatonin on plasma 8-OHdG level in SHRs
treated with L-NAME. *p < 0.05 vs. control. yp < 0.05 vs. L-NAME group. 8-OHdGZ 8-hydroxydeoxyguanosine; L-NAMEZ NG-nitro-L-
arginine methyl ester; SHR Z spontaneously hypertensive rat.
194 M.-C. Cheng et alto-ADMA ratio in the kidney. Because improvements in the
arginine-to-ADMA ratio by angiotensin AT1 receptor
blockers prevent hypertension and kidney damage in fawn-
hooded hypertensive rats,12 our findings suggest that the
protective effects of melatonin on hypertension and kidney
damage are, at least in part, due to restoration of the
arginine-to-ADMA ratio. These observations are in agree-
ment with our previous report which showed that 24-week-
old SHRs are resistant to kidney injury by restoration of the
renal ADMA level and arginine-to-ADMA ratio.7 The arginine-
to-ADMA ratio has been considered as a marker of NO
bioavailability. Our data showed that the changes of NOproduction detected by EPR were consistent with the
arginine-to-ADMA ratio among the three groups.
How does melatonin prevent the increases of renal ADMA
levels in L-NAME-treated SHRs (Figure 1B)? We found that L-
NAME reduced renal DDAH activity, whereas melatonin
significantly increased DDAH activity in the SHR kidney. Ac-
tivity of DDAH was suppressed by reactive oxygen species
(ROS), whereas melatonin could block ROS-induced
decreased DDAH activity.13 We determined ROS-mediated
8-OHdG staining (an oxidative stress marker) and found
that melatonin partially attenuates L-NAME-reduced stain-
ing intensities of 8-OHdG in the SHR kidney. Also, the changes
Melatonin in SHRs with L-NAME 195of 8-OHdG staining in the kidney developed in parallel with
the plasma levels of 8-OHdG among the three groups. These
findings support the possibility that melatonin reduced
oxidative stress and restored DDAH activity, to reduce ADMA
accumulation in L-NAME-treated SHR kidney.
Similar to other models of experimentally induced CKD,
increases of ADMA and oxidative stress are observed in this
L-NAME/SHR model. Specific therapy targeting the
DDAHeADMA pathway may offer a promising approach to
delay CKD progression. Additionally, elucidation of the
differences and similarities in the mechanisms involved in
the progression of CKD in children and adults may provide
insights into prevention of childhood CKD.
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